Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMMP Catalyst Timeline
Dated clinical, regulatory and corporate events for Immutep Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immutep Limited
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How IMMP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-10 | IMP761 | Phase 1 data presentation | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| eftilagimod alfa (efti / IMP321) BiologicsNCT06726265 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | ACTIVE NOT_RECRUITING | 756 | Sep 1, 2029 | ||||||
| IMP321 BiologicsCompletedNCT02614833 | Adenocarcinoma Breast Stage IV | Phase 2 | COMPLETED | 242 | May 1, 2021 | ||||||
| eftilagimod alfa (efti / IMP321) BiologicsCompletedNCT03625323 | NSCLC | Phase 2 | COMPLETED | 187 | Nov 25, 2024 | ||||||
| eftilagimod alfa (efti / IMP321) BiologicsCompletedNCT04811027 | HNSCC | Phase 2 | COMPLETED | 171 | Nov 5, 2025 | ||||||
| IMP321 BiologicsCompletedNCT00349934 | Metastatic Breast Cancer | Phase 1 | COMPLETED | 33 | Jan 1, 2010 | ||||||
| IMP321 BiologicsCompletedNCT00351949 | Stage IV Renal Cell Carcinoma | Phase 1 | COMPLETED | 24 | Oct 1, 2008 | ||||||
| IMP321 Small MoleculesCompletedNCT02676869 | Stage IV Melanoma | Phase 1 | COMPLETED | 24 | Dec 1, 2019 | ||||||
| IMP761 BiologicsCompletedNCT06637865 | Undisclosed | Phase 1 | COMPLETED | 79 | Aug 27, 2026 | ||||||
| Cvac BiologicsMarketedNCT01068509 | Epithelial Ovarian Cancer | Approved | COMPLETED | 63 | Apr 1, 2015 | ||||||
| MUC1 Dendritic Cell Vaccine VaccinesMarketedNCT01617629 | Epithelial Ovarian Cancer | Approved | COMPLETED | 9 | Apr 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMMP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IMP761 | Phase 1 | 2026-11-08 | statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers; well tolerated across all seven dose levels; no serious or severe adverse events reportedRead More | IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in IMMP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0.3 % | 9.68 M | 2.50 M |
Ownership Trends
IMMP Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How IMMP ranks across every disease it competes in
IMMP News
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
Immutep Limited announced the grant of a new US patent for efti-based combination therapies, expanding its patent portfolio to five patents. The new patent covers combinations of efti with PD-1 pathway inhibitors, enhancing its protection in cancer treatment. CEO Marc Voigt emphasized the strategic importance of this patent for future development opportunities.
Read more →Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
Immutep announced preliminary survival data from the EFTISARC-NEO trial, showing promising outcomes for patients with resectable soft tissue sarcoma. The study reported 12-month disease-free survival rates of 81.1%, local recurrence-free survival at 94.1%, and distant metastasis-free survival at 86.2%. Further analyses will be presented at the CTOS 2026 Annual Meeting.
Read more →IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
Immutep Limited announced positive results from its Phase I study of IMP761, showing significant inhibition of T-cell-driven immune responses in healthy volunteers. The drug was well tolerated across all doses, and the ongoing study has not revealed new safety concerns. Results from the multiple ascending dose portion are expected in H1 CY2027.
Read more →Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Immutep Limited announced upcoming poster presentations for its MHC Class II agonist, eftilagimod alfa, at CTOS 2026 and ESMO 2026. The presentations will include survival data from the EFTISARC-NEO Phase II trial and final median overall survival results from the TACTI-003 Phase IIb trial. These events will take place in November and December 2026.
Read more →Immutep Quarterly Activities Report Q1 FY27
Immutep Limited reported its Q1 FY27 activities, focusing on the registration-directed development of efti for HNSCC and STS. The EFTISARC-NEO trial showed promising results, while the TACTI-004 study was discontinued due to unexpected outcomes. The company maintains a strong cash position, with funding expected to last into H1 CY28.
Read more →Immutep Receives A$2.16 million French R&D Tax Incentive
Immutep Limited announced it received A$2.16 million from the French Government under the CIR tax incentive for R&D activities in 2025. This funding will support its ongoing research for product candidates eftilagimod alfa and IMP761. The company also received a cash rebate from the Australian Government and is eligible for Germany's R&D tax incentive.
Read more →Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Immutep presented quality of life data from the EFTISARC-NEO Phase II trial at ESMO 2026. The trial evaluated efti in combination with pembrolizumab and radiotherapy for soft tissue sarcoma. Results showed stable quality of life during treatment and significant improvements in patient-reported outcomes after surgery. Efti's safety profile supports its use in combination therapies.
Read more →Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
Immutep Limited announced that a late-breaking abstract on IMP761 has been accepted for poster presentation at ACR Convergence 2026. The poster will showcase data from a Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, conducted in healthy volunteers. The study aims to evaluate the drug's immunosuppressive effects and its potential in treating autoimmune diseases.
Read more →Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
Immutep Limited has announced that Monash University received a grant of A$652,248 from the Australian Research Council to support ongoing research into LAG-3. This funding will enhance their collaboration, which has previously led to significant findings regarding LAG-3's role in immune response regulation. The project aims to further explore LAG-3's interactions and its therapeutic potential.
Read more →Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immutep Limited has received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement. The company's American Depositary Shares (ADSs) traded above $1.00 for 10 consecutive business days, resolving a previous deficiency. This compliance is crucial for maintaining its listing on the Nasdaq Global Market.
Read more →Immutep Receives ~A$0.86 Million R&D Tax Incentive
Immutep Limited has secured an A$856,669 cash rebate from the Australian government's R&D tax incentive program for eligible activities in the 2025 fiscal year. The company is also eligible for R&D tax incentives in France and Germany, which will support its ongoing research into product candidates efti and IMP761. However, the timing and amount of future payments remain uncertain due to regulatory processes.
Read more →Change to American Depositary Share Ratio
Immutep Limited announced a change in the ratio of its American Depositary Shares (ADSs) from 1:10 to 1:200, effective September 28, 2026. This adjustment is a strategic move to comply with Nasdaq's minimum bid price requirement after the ADSs traded below $1.00 for 30 consecutive days. The change does not impact the number of ordinary shares or the company’s capital structure.
Read more →Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Immutep Limited has outlined a focused development strategy for eftilagimod alfa, targeting head and neck squamous cell carcinoma and soft tissue sarcoma. The company has contracted a new manufacturing run to address issues identified in the TACTI-004 study. Preparations for future clinical trials are underway, with a targeted start in the second half of 2027.
Read more →Immutep Quarterly Activities Report Q4 FY26
Immutep Limited reported positive developments in its quarterly activities for Q4 FY26, highlighting a pooled analysis of efti trials that demonstrated a 7.7-month survival benefit. The company also shared promising results from its IMP761 trial, while addressing the discontinuation of the TACTI-004 trial due to futility. Financially, Immutep remains strong with significant cash reserves.
Read more →Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Immutep Limited announced that an abstract for the EFTISARC-NEO Phase II trial has been accepted for presentation at the ESMO Congress 2026 in Madrid. The abstract will feature health-related quality of life data regarding their first-in-class MHC Class II agonist, eftilagimod alfa. The full abstract will be published on the ESMO website on October 19, 2026.
Read more →Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Immutep Limited has secured a fourth U.S. patent for its immunotherapy, eftilagimod alfa, which is designed for cancer treatment in combination with PD-1 pathway inhibitors. This new patent enhances the company's intellectual property portfolio, supporting future development and business opportunities. Eftilagimod alfa is currently being evaluated for various solid tumors and has received Fast Track designation from the FDA.
Read more →Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Immutep announced positive results from the INSIGHT-003 Phase I trial, showing a median overall survival of 30.9 months in patients with non-squamous NSCLC. The results are particularly encouraging for patients with low PD-L1 expression, who typically have fewer treatment options. However, the TACTI-004 trial was discontinued after a futility analysis indicated inferior outcomes compared to the control arm.
Read more →Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
Immutep Limited announced positive interim Phase I data for its LAG-3 agonist antibody, IMP761, which showed favorable safety and pharmacodynamic activity in healthy volunteers. The study met its primary endpoint and demonstrated significant immunosuppressive effects, supporting further clinical investigation in autoimmune diseases. Additional updates are expected in H2 CY2026.
Read more →Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Immutep Limited announced positive results from five clinical trials evaluating eftilagimod alfa in late-stage cancer patients. The combination of eftilagimod alfa with standard-of-care therapies led to a significant increase in overall survival, particularly among patients showing an immune response. The findings suggest a strong link between immune activation and improved clinical outcomes across various cancer types.
Read more →Immutep Quarterly Activities Report & Appendix 4C Q3 FY26
Immutep has decided to discontinue the TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer based on a recommendation from the Independent Data Monitoring Committee. The interim futility analysis indicated that patients receiving the treatment were underperforming compared to those on a placebo. Although this outcome was disappointing, Immutep continues to explore other avenues for its clinical programs, including ongoing trials like INSIGHT-003, which show favorable results. The company's financial position remains solid with a cash balance of approximately A$110.6 million.
Read more →